IKT · Company research
Inhibikase Therapeutics, Inc. Common Stock (IKT): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
17records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| IKT Initiated Coverage by Chardan Capital -- Rating Set to Neutr - GuruFocus | IKT Initiated Coverage by Chardan Capital -- Rating Set to Neutr GuruFocus | View source ↗ | GuruFocus | Oct 13, 2026 | neutral | 0 | 0.6 |
| Two new hires receive options to buy up to 128,000 Inhibikase shares - Stock Titan | Two new hires receive options to buy up to 128,000 Inhibikase shares Stock Titan | View source ↗ | Stock Titan | Oct 2, 2026 | neutral | 0 | 0.6 |
| Inhibikase Therapeutics (NASDAQ:IKT) Is In A Good Position To Deliver On Growth Plans - Simply Wall Street | Inhibikase Therapeutics (NASDAQ:IKT) Is In A Good Position To Deliver On Growth Plans Simply Wall Street | View source ↗ | Simply Wall Street | Sep 26, 2026 | neutral | 0 | 0.6 |
| Inhibikase (NASDAQ: IKT) tests PAH pill in pivotal global trial - Stock Titan | Inhibikase (NASDAQ: IKT) tests PAH pill in pivotal global trial Stock Titan | View source ↗ | Stock Titan | Sep 8, 2026 | neutral | 0 | 0.6 |
| Inhibikase Therapeutics (IKT) Holds Steady at $2.41 as Shares Consolidate Between $2.29 Support and $2.53 Resistance - Anchored VWAP - https://www.dars.gov.et/ | Inhibikase Therapeutics (IKT) Holds Steady at $2.41 as Shares Consolidate Between $2.29 Support and $2.53 Resistance - Anchored VWAP https://www.dars.gov.et/ | View source ↗ | https://www.dars.gov.et/ | Aug 16, 2026 | neutral | 0 | 0.6 |
| IKT Forecast — Price Target — Prediction for 2027 - TradingView | IKT Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| A Look At Inhibikase Therapeutics (IKT) Valuation After New FDA Designations And Phase 2a Trial Progress - Simply Wall Street | A Look At Inhibikase Therapeutics (IKT) Valuation After New FDA Designations And Phase 2a Trial Progress Simply Wall Street | View source ↗ | Simply Wall Street | Feb 27, 2026 | neutral | 0 | 0.6 |
| Inhibikase Therapeutics, Inc. Common Stock (IKT) Stock Price: Oct 9 Close $1.97 - Gotrade | Inhibikase Therapeutics, Inc. Common Stock (IKT) Stock Price: Oct 9 Close $1.97 Gotrade | View source ↗ | Gotrade | Feb 27, 2026 | neutral | 0 | 0.6 |
| $IKT stock is up 13% today. Here's what we see in our data. - Quiver Quantitative | $IKT stock is up 13% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Feb 23, 2026 | neutral | 0 | 0.6 |
| IKT Stock Bounces Amid Steady Growth Potential - StocksToTrade | IKT Stock Bounces Amid Steady Growth Potential StocksToTrade | View source ↗ | StocksToTrade | Feb 23, 2026 | neutral | 0 | 0.6 |
| Inhibikase Therapeutics Stock Faces Challenges Amid Financial Uncertainty - Timothy Sykes | Inhibikase Therapeutics Stock Faces Challenges Amid Financial Uncertainty Timothy Sykes | View source ↗ | Timothy Sykes | Feb 23, 2026 | neutral | 0 | 0.6 |
| Inhibikase Therapeutics: A Surge in Market Interest on Recent Developments - timothysykes.com | Inhibikase Therapeutics: A Surge in Market Interest on Recent Developments timothysykes.com | View source ↗ | timothysykes.com | Feb 23, 2026 | neutral | 0 | 0.6 |
| Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks - Yahoo Finance | Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks Yahoo Finance | View source ↗ | Yahoo Finance | Feb 22, 2026 | neutral | 0 | 0.6 |
| $IKT stock is up 19% today. Here's what we see in our data. - Quiver Quantitative | $IKT stock is up 19% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Dec 26, 2025 | neutral | 0 | 0.6 |
| Inhibikase Therapeutics (IKT) Stock Forecast and Price Target 2026 $IKT - MarketBeat | Inhibikase Therapeutics (IKT) Stock Forecast and Price Target 2026 $IKT MarketBeat | View source ↗ | MarketBeat | Sep 1, 2025 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Mar 21, 2024 | neutral | 0 | 0.6 |
| Inhibikase: IKT Stock Price Quote & News - Robinhood | Inhibikase: IKT Stock Price Quote & News Robinhood | View source ↗ | Robinhood | Jul 26, 2023 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.